Founded with a mission to revolutionize reconstructive plastic surgery, inSoma Bio develops innovative products that leverage natural tissue instead of synthetic implants and fillers. Their core vision is to enhance surgical outcomes by using a patient's own tissue, thereby improving procedures such as breast and facial reconstruction. By borrowing nature’s designs, inSoma Bio aims to provide safer, more effective solutions for reconstructive surgery, focusing on the medical and healthcare markets.
Notable figures affiliated with inSoma Bio include Dr. Heather Brennan and Dr. Juliana Blum, who serve on the Board of Directors, and Thalia Charles, the Head of Regulatory Affairs. The company has achieved significant milestones, including raising $0.5 million in a seed funding round. Through these efforts, inSoma Bio has made a substantial impact on the field of reconstructive surgery, offering promising alternatives to traditional synthetic methods.
